194 related articles for article (PubMed ID: 34125445)
1. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
[TBL] [Abstract][Full Text] [Related]
2. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
[TBL] [Abstract][Full Text] [Related]
3. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
[TBL] [Abstract][Full Text] [Related]
4. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract][Full Text] [Related]
5. High B7-H3 expression is linked to increased risk of prostate cancer progression.
Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
[TBL] [Abstract][Full Text] [Related]
6. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
7. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
[TBL] [Abstract][Full Text] [Related]
8. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.
Kang N; Xue H; Lin YY; Dong X; Classen A; Wu R; Jin Y; Lin D; Volik S; Ong C; Gleave M; Collins C; Wang Y
Cancer Gene Ther; 2023 Oct; 30(10):1382-1389. PubMed ID: 37452083
[TBL] [Abstract][Full Text] [Related]
9. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
[TBL] [Abstract][Full Text] [Related]
10. Expression status of PD-L1 and B7-H3 in mesothelioma.
Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
[TBL] [Abstract][Full Text] [Related]
11. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
13. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
[TBL] [Abstract][Full Text] [Related]
15. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer.
Shi X; Day A; Bergom HE; Tape S; Baca SC; Sychev ZE; Larson G; Bozicevich A; Drake JM; Zorko N; Wang J; Ryan CJ; Antonarakis ES; Hwang J
NPJ Precis Oncol; 2022 Nov; 6(1):80. PubMed ID: 36323882
[TBL] [Abstract][Full Text] [Related]
16. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G
Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597
[TBL] [Abstract][Full Text] [Related]
17. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
18. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
19. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of VISTA, B7-H3, and PD-L1 in glioma.
Wang LC; Wang YL; He B; Zheng YJ; Yu HC; Liu ZY; Fan RR; Zan X; Liang RC; Wu ZP; Tang X; Wang GQ; Xu JG; Zhou LX
Clin Immunol; 2022 Dec; 245():109178. PubMed ID: 36368642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
